Overview

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

Status:
RECRUITING

Trial end date:
2028-10-14

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).

Phase:

PHASE3

Details

Lead Sponsor:

Amgen

Treatments:

AMG 757
durvalumab